BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
2022; Massachusetts Medical Society; Volume: 387; Issue: 3 Linguagem: Inglês
10.1056/nejmoa2205011
ISSN1533-4406
AutoresChandra J. Cohen-Stavi, Ori Magen, Noam Barda, Shlomit Yaron, Alon Peretz, Doron Netzer, Carlo Giaquinto, Ali Judd, Leonard Leibovici, Miguel A. Hernán, Marc Lipsitch, Ben Y. Reis, Ran D. Balicer, Noa Dagan,
Tópico(s)Long-Term Effects of COVID-19
ResumoLimited evidence is available on the real-world effectiveness of the BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) and specifically against infection with the omicron variant among children 5 to 11 years of age.
Referência(s)